<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133237</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02005</org_study_id>
    <nct_id>NCT00133237</nct_id>
  </id_info>
  <brief_title>Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)</brief_title>
  <official_title>Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of sirolimus- and paclitaxel-eluting
      stents for treatment of unprotected left main coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the advent of coronary stents and improvements in periprocedural antithrombotic regimen,
      the spectrum of indications of percutaneous coronary interventions has continuously expanded
      for patients with coronary heart disease, gaining ground in what have been traditionally
      considered as domains of coronary bypass surgery. Several groups reported the outcomes of
      patients with unprotected left main coronary artery (LMCA) disease treated with stenting.
      Most of them found that LMCA stenting was feasible and safe, and, in low-risk patients, it
      was associated with minimal periprocedural complications and low long-term morbidity and
      mortality. Despite these encouraging reports, a widespread use of this technique has been
      hampered by the still high incidence of restenosis. It is commonly accepted that coronary
      bypass graft surgery and stenting for unprotected LMCA disease are associated with similar
      rates of mortality, and that the higher incidence of restenosis and greater need for
      revascularization procedures after LMCA stenting remain the major contributors for the
      observed difference in clinical efficacy between both therapies. The recent introduction of
      stents eluting anti-restenotic drugs, with sirolimus and paclitaxel the most studied
      compounds, has opened new perspectives for the prevention of restenosis. Several randomized
      trials have reported excellent results in the reduction of restenosis and need for
      reinterventions with drug-eluting stents (DES). Although, none of these trials studied the
      benefit of DES for lesions located in the LMCA, their results suggested that use of these new
      devices may be particularly helpful for the reduction of restenosis in the group of patients
      with left main trunk disease. This is supported by the findings of several series of patients
      with unprotected LMCA disease who have been successfully treated with DES. Importantly, for
      patients who are unable to undergo CABG due to cardiac surgeons' refusal (poor surgical
      candidates) or their own unwillingness, stenting with DES remains the only revascularization
      alternative. Recent guidelines of PCI recommend stenting, preferentially with DES, for
      unprotected LMCA in the absence of other revascularization options.

      Comparison:

      Sirolimus-eluting stents compared with paclitaxel-eluting stent for treatment of lesions
      allocated at left main trunk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events (composite of death, myocardial infarction and target lesion revascularization) at one year</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic restenosis at 6-9 month follow-up angiography (based on left main area analysis)</measure>
    <time_frame>6-9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">607</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent (Cypher)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel-eluting stent (Taxus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting stent</intervention_name>
    <description>cypher stent is implanted due to randomization.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting stent</intervention_name>
    <description>taxus stent is implanted due to randomization.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Taxus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of ≥50% stenosis located in unprotected LMCA who are unable to undergo
             coronary artery bypass graft (CABG)

          -  Pretreatment with a loading dose of 300-600 mg clopidogrel

          -  Informed, written consent

        Exclusion Criteria:

          -  Cardiogenic shock;

          -  ST-segment elevation acute myocardial infarction within 48 h from symptom onset;

          -  In-stent restenosis;

          -  Malignancies or other comorbid conditions with life expectancy less than one year;

          -  Prior coronary artery bypass surgery with revascularization of left anterior
             descending (LAD) and/or left circumflex (LCx) coronary artery

          -  Planned staged percutaneous coronary intervention (PCI) procedure within 30 days from
             index procedure or prior PCI within the last 30 days

          -  Left main size &gt;4.5mm

          -  An elective surgical procedure is planned during the first six months post enrolment;

          -  Known allergy to the study medications

          -  Pregnancy

          -  Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schömig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ellis SG, Tamai H, Nobuyoshi M, Kosuga K, Colombo A, Holmes DR, Macaya C, Grines CL, Whitlow PL, White HJ, Moses J, Teirstein PS, Serruys PW, Bittl JA, Mooney MR, Shimshak TM, Block PC, Erbel R. Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994-1996. Circulation. 1997 Dec 2;96(11):3867-72.</citation>
    <PMID>9403609</PMID>
  </reference>
  <reference>
    <citation>Park SJ, Park SW, Hong MK, Cheong SS, Lee CW, Kim JJ, Hong MK, Mintz GS, Leon MB. Stenting of unprotected left main coronary artery stenoses: immediate and late outcomes. J Am Coll Cardiol. 1998 Jan;31(1):37-42.</citation>
    <PMID>9426015</PMID>
  </reference>
  <reference>
    <citation>Takagi T, Stankovic G, Finci L, Toutouzas K, Chieffo A, Spanos V, Liistro F, Briguori C, Corvaja N, Albero R, Sivieri G, Paloschi R, Di Mario C, Colombo A. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation. 2002 Aug 6;106(6):698-702.</citation>
    <PMID>12163430</PMID>
  </reference>
  <reference>
    <citation>Ellis SG, Hill CM, Lytle BW. Spectrum of surgical risk for left main coronary stenoses: benchmark for potentially competing percutaneous therapies. Am Heart J. 1998 Feb;135(2 Pt 1):335-8.</citation>
    <PMID>9489985</PMID>
  </reference>
  <reference>
    <citation>Chieffo A, Stankovic G, Bonizzoni E, Tsagalou E, Iakovou I, Montorfano M, Airoldi F, Michev I, Sangiorgi MG, Carlino M, Vitrella G, Colombo A. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation. 2005 Feb 15;111(6):791-5. Epub 2005 Feb 7.</citation>
    <PMID>15699254</PMID>
  </reference>
  <reference>
    <citation>Valgimigli M, van Mieghem CA, Ong AT, Aoki J, Granillo GA, McFadden EP, Kappetein AP, de Feyter PJ, Smits PC, Regar E, Van der Giessen WJ, Sianos G, de Jaegere P, Van Domburg RT, Serruys PW. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation. 2005 Mar 22;111(11):1383-9.</citation>
    <PMID>15781749</PMID>
  </reference>
  <reference>
    <citation>Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr;26(8):804-47. Epub 2005 Mar 15.</citation>
    <PMID>15769784</PMID>
  </reference>
  <results_reference>
    <citation>Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A; LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2009 May 12;53(19):1760-8. doi: 10.1016/j.jacc.2009.01.035.</citation>
    <PMID>19422982</PMID>
  </results_reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>March 12, 2010</last_update_submitted>
  <last_update_submitted_qc>March 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Albert Schömig</name_title>
    <organization>Deutsches Herzzentrum Muenchen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

